US 11,787,848 B2
CD33 specific chimeric antigen receptors
Rutul Shah, Boyds, MD (US); Tim Chan, Frederick, MD (US); Peter Emtage, Lafayette, CA (US); and Ramya Yarlagadda, Gaithersburg, MD (US)
Assigned to PRECIGEN, INC., Germantown, MD (US)
Filed by Precigen, Inc., Germantown, MD (US)
Filed on Jun. 7, 2017, as Appl. No. 15/616,869.
Claims priority of provisional application 62/347,503, filed on Jun. 8, 2016.
Prior Publication US 2018/0002397 A1, Jan. 4, 2018
Int. Cl. C07K 14/705 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 14/71 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 14/70503 (2013.01) [A61K 39/001104 (2018.08); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/57 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01)] 45 Claims
 
1. A vector comprising a backbone and a nucleic acid sequence encoding:
(A) a cell tag comprising an amino acid sequence having at least 95% identity with the full length of SEQ ID NO: 54; and
(B) a chimeric antigen receptor (CAR) comprising:
(1) a CD33 antigen binding domain comprising:
(a) the amino acid sequence of SEQ ID NO: 1 and the amino acid sequence of SEQ ID NO: 3;
(b) the amino acid sequence of SEQ ID NO: 9 and the amino acid sequence of SEQ ID NO: 10;
(c) amino acid sequence of SEQ ID NO: 11 and the amino acid sequence of SEQ ID NO: 12; or
(d) the amino acid sequence of the full length of SEQ ID NO: 13 and the amino acid sequence of SEQ ID NO: 14;
(2) a stalk domain comprising: (a) a hinge region from IgG1; (b) a hinge region from IgG4; (c) the CH2CH3 region of immunoglobulin; or (d) the CD8alpha hinge domain;
(3) a transmembrane domain that: (a) comprises the transmembrane region of: the alpha chain of a T-cell receptor, the beta chain of a T-cell receptor, the zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8alpha, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154; or (b) is synthetic and comprises predominantly hydrophobic residues;
(4) a costimulatory signaling domain comprising 4-1BB, CD28, or both; and
(5) a CD3 zeta signaling domain.